| 1. | tv52898 | |
| 2. | jesacoyote77 | |
| 3. | supper3638 | |
| 4. | dmchof94 | |
| 5. | ftbensoldier |
Top Board Researchers
These are the top researchers based on quality of posts as voted by board members. Typically they know their stuff and are a great
way to catch up on what the company is all about.
HOW DO I BECOME ONE?
Just do great research! As other members approve of your posts, you earn points that move you up the ranks.| 1. | jesacoyote77 04/17/2018 Basilea licenses late-stage oncology drug candidate derazantinib from ArQule |
| 2. | supper3638 06/13/2018 Oppenheimer initiates as an outperform, $7PT |
| 3. | jesacoyote77 04/17/2018 early? nah |
| 4. | tv52898 02/22/2018 seems accurate |
| 5. | dmchof94 02/22/2018 {Image} |
| 6. | dmchof94 04/17/2018 Looking to add some |
| 7. | supper3638 04/17/2018 Enters into license agreement with Basilea Pharmaceutica; Basilea will make an upfront payment to ArQule of … |
| 8. | supper3638 02/07/2018 ArQule and Roivant Sciences initiate a collaboration to pursue the development of derazantinib in Greater Ch… |
| 9. | jesacoyote77 02/04/2018 B. Riley FBR, Inc. raises to buy |
| 10. | jesacoyote77 02/22/2018 Wow, this is a double |
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW
ArQule, Inc.
- ARQL
- Public Stock Message Board
Filtering by:
-
To use your chart in a post, click the
icon above the chart. From there you can get the chart link or download the image.